You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國同輻(01763.HK):高端放射治療設備准予許可28台,中核安科鋭旗下兩款產品佔比93%
格隆匯 08-02 21:59

格隆匯8月2日丨中國同輻(01763.HK)宣佈,2021年7月30日,國家衞生健康委2021年第3次委主任會議已審議通過2020年甲類大型醫用設備配置許可名單。高端放射治療設備准予許可28台,其中螺旋斷層放射治療系統(Tomo)10台;X線立體定向放射治療系統(CyberKnife)16台,中核安科鋭旗下兩款產品佔比93%。"十三五"期間高端放療設備共頒發許可118台,中核安科鋭旗下上述兩款產品累計獲得配置證100張,佔比85%。

中核安科鋭是中國核工業集團有限公司旗下中國同輻股份有限公司(01763.HK)與美國安科鋭公司(NASDAQ: ARAY)於2019年3月26日在天津市東麗開發區合資設立,未來將在中國提供腫瘤精準放射治療、科技研發、生產及服務的系統解決方案。中核安科鋭自2019年3月成立以來,秉承"創新科技為愛而生"的企業使命,植根中國,持續創新發展,助力專業醫務人員為患者提供優質的醫療服務。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account